Stockreport

ASLAN Pharmaceuticals Provides TREK-DX Study Update and Highlights Potential of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients

ASLAN Pharmaceuticals Limited - American Depositary Shares  (ASLN) 
US:NASDAQ Investor Relations: ir.aslanpharma.com
PDF TREK-DX, the first randomized, double-blind, placebo-controlled study to be conducted in a dupilumab-experienced atopic dermatitis (AD) patient population, has started e [Read more]